BICO Group AB
STO:BICO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
34.02
69.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
BICO Group AB
BICO Group AB
Income from Continuing Operations
BICO Group AB
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BICO Group AB
STO:BICO
|
Income from Continuing Operations
-kr1.7B
|
CAGR 3-Years
-226%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
AddLife AB
STO:ALIF B
|
Income from Continuing Operations
kr192m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Biotage AB
STO:BIOT
|
Income from Continuing Operations
kr257m
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
17%
|
|
|
G
|
Genovis AB
STO:GENO
|
Income from Continuing Operations
kr17.3m
|
CAGR 3-Years
14%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
MedCap AB (publ)
STO:MCAP
|
Income from Continuing Operations
kr229m
|
CAGR 3-Years
43%
|
CAGR 5-Years
38%
|
CAGR 10-Years
29%
|
|
|
M
|
Magle Chemoswed Holding AB
STO:MAGLE
|
Income from Continuing Operations
kr12.2m
|
CAGR 3-Years
89%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
BICO Group AB
Glance View
BICO Group AB is a bioconvergence company, which engages in the provision of technologies, products, and services to create, understand and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 890 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
See Also
What is BICO Group AB's Income from Continuing Operations?
Income from Continuing Operations
-1.7B
SEK
Based on the financial report for Dec 31, 2023, BICO Group AB's Income from Continuing Operations amounts to -1.7B SEK.
What is BICO Group AB's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-226%
Over the last year, the Income from Continuing Operations growth was -1 827%. The average annual Income from Continuing Operations growth rates for BICO Group AB have been -226% over the past three years .
You don't have any saved screeners yet
